Ask AI
ProCE Banner Activity

Answers to Key Questions in the Multidisciplinary Management of Extensive-Stage SCLC Using Novel Therapies

Clinical Thought

Read this commentary with expert’s thoughts and considerations for the management of extensive-stage SCLC in the first-line setting and at disease recurrence using emerging new therapies.

Released: January 22, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Christine L. Hann, MD, PhD

Associate Professor of Oncology
Director, Small Cell Lung Cancer Therapeutics
Johns Hopkins University School of Medicine
Baltimore, Maryland

Christine L. Hann, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Daiichi Sankyo, Genentech; researcher (paid to institution): AbbVie, Amgen, AstraZeneca, Daiichi Sankyo.

Ticiana Leal, MD

Professor
Department of Hematology & Oncology
Director, Thoracic Oncology
Medical Director, Clinical Trials Office
Winship Cancer Institute
Emory University
Atlanta, Georgia

Ticiana Leal, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Catalyst, Genentech, Gilead, Jazz, Johnson & Johnson, Merck, Molecular Partners, Naterra, Novocure, Pfizer, Regeneron, Roche, Sanofi, Summit, Synthekine.